08:34 AM EST, 11/18/2024 (MT Newswires) -- Bausch Health Companies ( BHC ) on Monday said its topical prescription treatment gel for acne vulgaris (Cabtreo) in patients 12 years of age and older received a reimbursement recommendation from Canada's Drug Agency (CDA, formerly Canadian Agency for Drugs and Technology in Health) and Quebec's Institut national d'excellence en sante et en services sociaux (INESSS).

Cabtreo is the only topical treatment for acne approved by Health Canada that includes an antibiotic, a retinoid and an antibacterial agent, Bausch Health ( BHC ) said.

"The positive recommendations of both CDA and INESSS are important steps in achieving the inclusion of Cabtreo on Canada's public drug plans and recognize this new treatment's value in helping Canadians with acne," said Amy Cairns, general manager, Bausch Health ( BHC ), Canada.

Bausch is down 0/4% to US$8.45 in U.S. premarket trade.